BACKGROUND: Aneurysmal subarachnoid haemorrhage (SAH) WFNS grade V is commonly known to be associated with high mortality and a very poor prognosis for survivors. Therefore, maximal invasive therapy is frequently delayed until any spontaneous improvement with or without an external ventricular drainage occurs. The aim of the study was to verify possible predictive factors and the probability of a favourable outcome in maximally treated patients. METHODS: One hundred and thirty-eight consecutive patients with WFNS grade V SAH were admitted between 03/2006 and 12/2010. Thirty-five patients died before aggressive therapy could proceed. One hundred and three patients received maximal treatment and were retrospectively evaluated. The outcome was assessed at discharge and in the follow-up with the Glasgow Outcome Scale. Univariate and multivariate linear regression models were performed to find predictors for an unfavourable outcome. RESULTS: Despite treatment, early mortality was 30 % (n = 31). At discharge, the rate of both vegetative and severely disabled patients was 27 % (n = 28). Favourable outcome at discharge was observed in 16 % (n = 16) of cases, whereas in the follow-up it rose to 26 % (n = 27). Multivariate full model regression identified intraventricular haematoma (IVH) and increasing age as independently predictive for poor outcome. CONCLUSIONS: Despite treatment, initial mortality and severe disability remain high. Nevertheless, a favourable outcome was achieved in 26 % of aggressively treated patients, rendering the withdrawal of maximal therapy for WFNS grade V SAH patients unacceptable today. In cases of old patients with IVH, the indication for aggressive therapy should be put in place more carefully due to a very poor prognosis.
BACKGROUND:Aneurysmal subarachnoid haemorrhage (SAH) WFNS grade V is commonly known to be associated with high mortality and a very poor prognosis for survivors. Therefore, maximal invasive therapy is frequently delayed until any spontaneous improvement with or without an external ventricular drainage occurs. The aim of the study was to verify possible predictive factors and the probability of a favourable outcome in maximally treated patients. METHODS: One hundred and thirty-eight consecutive patients with WFNS grade V SAH were admitted between 03/2006 and 12/2010. Thirty-five patients died before aggressive therapy could proceed. One hundred and three patients received maximal treatment and were retrospectively evaluated. The outcome was assessed at discharge and in the follow-up with the Glasgow Outcome Scale. Univariate and multivariate linear regression models were performed to find predictors for an unfavourable outcome. RESULTS: Despite treatment, early mortality was 30 % (n = 31). At discharge, the rate of both vegetative and severely disabled patients was 27 % (n = 28). Favourable outcome at discharge was observed in 16 % (n = 16) of cases, whereas in the follow-up it rose to 26 % (n = 27). Multivariate full model regression identified intraventricular haematoma (IVH) and increasing age as independently predictive for poor outcome. CONCLUSIONS: Despite treatment, initial mortality and severe disability remain high. Nevertheless, a favourable outcome was achieved in 26 % of aggressively treated patients, rendering the withdrawal of maximal therapy for WFNS grade V SAHpatients unacceptable today. In cases of old patients with IVH, the indication for aggressive therapy should be put in place more carefully due to a very poor prognosis.
Authors: Daniel W Zumofen; Michel Roethlisberger; Rita Achermann; Schatlo Bawarjan; Martin N Stienen; Christian Fung; Donato D'Alonzo; Nicolai Maldaner; Andrea Ferrari; Marco V Corniola; Daniel Schoeni; Johannes Goldberg; Daniele Valsecchi; Thomas Robert; Rodolfo Maduri; Martin Seule; Jan-Karl Burkhardt; Serge Marbacher; Philippe Bijlenga; Kristine A Blackham; Heiner C Bucher; Luigi Mariani; Raphael Guzman Journal: Neurosurg Rev Date: 2018-02-10 Impact factor: 3.042
Authors: Vishank A Shah; Syed Omar Kazmi; Rahul Damani; Alyssa Hartsell Harris; Samuel F Hohmann; Eusebia Calvillo; Jose I Suarez Journal: Front Neurol Date: 2022-06-16 Impact factor: 4.086
Authors: Jordi de Winkel; Tim Y Cras; Ruben Dammers; Pieter-Jan van Doormaal; Mathieu van der Jagt; Diederik W J Dippel; Hester F Lingsma; Bob Roozenbeek Journal: BMC Neurol Date: 2022-06-30 Impact factor: 2.903
Authors: Johannes Walter; Martin Grutza; Markus Möhlenbruch; Dominik Vollherbst; Lidia Vogt; Andreas Unterberg; Klaus Zweckberger Journal: J Clin Med Date: 2022-04-05 Impact factor: 4.241
Authors: Peter Y M Woo; Joanna W K Ho; Natalie M W Ko; Ronald P T Li; Leo Jian; Alberto C H Chu; Marco C L Kwan; Yung Chan; Alain K S Wong; Hoi-Tung Wong; Kwong-Yau Chan; John C K Kwok Journal: BMC Neurol Date: 2020-11-03 Impact factor: 2.474